C-Rad AB (publ) Market Cap ($82.28 Million)
Market Cap & Net Worth: C-Rad AB (publ) (CRAD-B)
C-Rad AB (publ) market cap. C-Rad AB (publ) (ST:CRAD-B) has a market capitalization of $82.28 Million (Skr764.53 Million) as of November 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #19743 globally and #346 in its home market, demonstrating a 12.80% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying C-Rad AB (publ)'s stock price Skr23.80 by its total outstanding shares 32123311 (32.12 Million). Also see CRAD-B cash generation efficiency for how efficiently the company converts equity into cash flow.
C-Rad AB (publ) Market Cap History (2015–2026)
C-Rad AB (publ) market cap history from 2015 to 2026. Data shows growth from $52.20 Million to $82.28 Million (2.93% CAGR). Check C-Rad AB (publ) (CRAD-B) stock price for real-time trading data and today's change.
C-Rad AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how C-Rad AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore CRAD-B net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.25x
C-Rad AB (publ)'s market cap is 0.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
10.52x
C-Rad AB (publ)'s market cap is 10.52 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $41.66 Million | $82.65 Million | -$31.21 Million | 0.50x | N/A |
| 2017 | $97.83 Million | $133.12 Million | -$10.91 Million | 0.73x | N/A |
| 2018 | $89.19 Million | $190.11 Million | $21.19 Million | 0.47x | 4.21x |
| 2019 | $153.84 Million | $205.39 Million | -$13.80 Million | 0.75x | N/A |
| 2020 | $166.63 Million | $221.63 Million | $14.37 Million | 0.75x | 11.60x |
| 2021 | $192.55 Million | $261.15 Million | $25.10 Million | 0.74x | 7.67x |
| 2022 | $131.71 Million | $301.33 Million | $7.48 Million | 0.44x | 17.61x |
| 2023 | $145.88 Million | $424.62 Million | $35.53 Million | 0.34x | 4.11x |
| 2024 | $103.71 Million | $469.00 Million | $56.45 Million | 0.22x | 1.84x |
| 2025 | $110.45 Million | $441.90 Million | $10.50 Million | 0.25x | 10.52x |
Competitor Companies of CRAD-B by Market Capitalization
Companies near C-Rad AB (publ) in the global market cap rankings as of November 4, 2026. Also see total assets of C-Rad AB (publ) for a full breakdown of the balance sheet.
Key companies related to C-Rad AB (publ) by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #110 globally with a market cap of $190.23 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #204 globally with a market cap of $119.12 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #226 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #110 | Abbott Laboratories | NYSE:ABT | $190.23 Billion | $109.40 |
| #204 | Stryker Corporation | NYSE:SYK | $119.12 Billion | $310.55 |
| #226 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $98.88 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of C-Rad AB (publ) (2015–2026)
Market capitalization of C-Rad AB (publ) from 2015 to today. Between 2015 and today, C-Rad AB (publ)'s market cap moved from $52.20 Million to $ 82.28 Million, with a yearly change of 2.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr82.28 Million | -25.51% |
| 2025 | Skr110.45 Million | +6.50% |
| 2024 | Skr103.71 Million | -28.91% |
| 2023 | Skr145.88 Million | +10.76% |
| 2022 | Skr131.71 Million | -31.60% |
| 2021 | Skr192.55 Million | +15.56% |
| 2020 | Skr166.63 Million | +8.31% |
| 2019 | Skr153.84 Million | +72.48% |
| 2018 | Skr89.19 Million | -8.83% |
| 2017 | Skr97.83 Million | +134.85% |
| 2016 | Skr41.66 Million | -20.20% |
| 2015 | Skr52.20 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of C-Rad AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $82.28 Million USD |
| MoneyControl | $82.28 Million USD |
| MarketWatch | $82.28 Million USD |
| marketcap.company | $82.28 Million USD |
| Reuters | $82.28 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About C-Rad AB (publ)
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solut… Read more